Condition: Acute Heart Failure (AHF) · Decompensated Chronic Heart Failure · Sponsor: Aarhus University Hospital
DESIGN: A prospective, multicenter, observational cohort study including 580 patients admitted for acute decompensated heart failure (ADHF). Ultrasound assessment of congestion (VExUS and LUS) will be performed serially during admission: within 48 hours of admission, at the time diuretic therapy is switched from intravenous to oral, and on the day of discharge. The discharge assessment will serve as the primary predictor. Treating physicians will be blinded to all ultrasound findings. Patients will be followed for 90 days by telephone follow-up and chart review for the primary endpoint, with extended chart review at one year for selected secondary endpoints. AIMS: To determine whether combined ultrasound assessment of venous (VExUS) and pulmonary congestion (LUS) at discharge predicts heart failure readmission and all-cause mortality in patients hospitalized with ADHF. HYPOTHESIS: Abnormal VExUS and/or LUS findings at discharge are associated with a higher risk of heart failure readmission and all-cause mortality after 90 days.
This description comes directly from the study's public registry record.
Kristoffer Berg-Hansen, MD, PhD · +4560540700 · krisbe@rm.dk
Always discuss trial participation with your own doctor first.
| Aarhus University Hospital - Department of Cardiology | Aarhus, Denmark | Recruiting |
| Copenhagen University Hospital, Amager and Hvidovre Hospital - Department of Cardiology | Copenhagen, Denmark | Not Yet Recruiting |
| Zealand University Hospital - Department of Cardiology | Roskilde, Denmark | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07682298